Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
End-of-day quote. End-of-day quote Korea Stock Exchange - 01/28
739000 KRW   +3.79%
01/27Samsung Biologics to Buy Biogen's Stake in JV
DJ
01/25Samsung Biologics' Q4 Net Profit Slumps, Revenue Jumps
MT
01/18S.Korea stocks hit 7-week closing low ahead of LGES IPO
RE
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Samsung Biologics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/15/2021 | 02:58am EST

Samsung Biologics Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 21,963.65 million compared to KRW 16,220.43 million a year ago. Net income was KRW 131,773.53 million compared to KRW 56,081.37 million a year ago. Basic earnings per share from continuing operations was KRW 1,992 compared to KRW 848 a year ago. Basic earnings per share was KRW 1,992 compared to KRW 848 a year ago. For the nine months, sales was KRW 86,071.38 million compared to KRW 32,932.84 million a year ago. Net income was KRW 314,271.53 million compared to KRW 144,753.07 million a year ago. Basic earnings per share from continuing operations was KRW 4,750 compared to KRW 2,188 a year ago. Basic earnings per share was KRW 4,750 compared to KRW 2,188 a year ago.


ę S&P Capital IQ 2021
All news about SAMSUNG BIOLOGICS CO.,LTD.
01/27Samsung Biologics to Buy Biogen's Stake in JV
DJ
01/25Samsung Biologics' Q4 Net Profit Slumps, Revenue Jumps
MT
01/18S.Korea stocks hit 7-week closing low ahead of LGES IPO
RE
01/18SAMSUNG BIOLOGICS : Prior Notice on Disclosure of Final Earnings
PU
01/14South Korean Stocks Fall for Second Day as Bank of Korea Raises Base Rate; Samsung Biol..
MT
01/13Samsung Biologics to Start Building Fifth Plant to Meet Higher Biopharmaceutical Produc..
MT
01/13S.Korean stocks end lower on options expiry; BOK in focus
RE
01/12South Korean Stocks Jump After US Fed Chief’s Less Hawkish Testimony; Hanmi Pharm..
MT
01/12S.Korean stocks post best day in 6 weeks on Powell remarks
RE
01/03S.Korea stocks begin 2022 with mild gains on trade data boost
RE
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Financials
Sales 2021 1 554 B 1,29 B 1,29 B
Net income 2021 437 B 0,36 B 0,36 B
Net Debt 2021 242 B 0,20 B 0,20 B
P/E ratio 2021 112x
Yield 2021 -
Capitalization 48 896 B 40 428 M 40 437 M
EV / Sales 2021 31,6x
EV / Sales 2022 25,8x
Nbr of Employees 2 886
Free-Float 25,0%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | A207940 | KR7207940008 | MarketScreener
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 739 000,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Seok-Woo Jung Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SAMSUNG BIOLOGICS CO.,LTD.-18.16%39 159
CSL LIMITED-14.20%84 148
WUXI BIOLOGICS (CAYMAN) INC.-19.72%41 757
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.13%32 161
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-15.23%27 227